United States, ex rel. Sanborn v. Athenahealth, Inc.United States, ex rel. Sanborn v. Athenahealth, Inc.
APPEALS FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS
[Hon. Nathaniel M. Gorton, U.S. District Judge]
Before Barron, Chief Judge, Lynch and Gelpi, Circuit Judges.
Hyland Hunt, with whom Ruthanne M. Deutsch, Deutsch Hunt PLLC, Suzanne E. Durrell, and Whistleblower Law Collaborative LLC were on brief, for appellants Lovell and McKusick.
Andrew D. Schlichter, with whom Joel D. Rohlf and Schlichter Bogard & Denton, LLP were on brief, for appellant Sanborn.
Sarah E. Walters, with whom Mark W. Pearlstein, Natasha L. Dobrott, and McDermott Will & Emery LLP were on brief, for appellee.
The first-to-file relator, Geordie Sanborn, appeals from the omission of certain claimed fees from his award of attorneys’ fees. Both appeals present questions of first impression for this court.
We affirm as to Lovell and McKusick on narrow reasoning, confined to the facts concerning the provisions of the government‘s settlement agreement. We conclude that Lovell and McKusick did not receive a relator‘s share and so are not entitled to attorneys’ fees. We leave for another day the issue of whether such fees are restricted to first-to-file relators. We also do not address different factual situations where the settlement agreement reached by the United States provides for payment of relator‘s shares to multiple relators. We affirm as to Sanborn, rejecting his argument under the text of
I.
A.
The False Claims Act imposes liability on any person who, inter alia, “knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval,”
B.
We recite only the necessary undisputed facts. Athena is a medical software company that sells health record services and other cloud-based products. Relator Sanborn works in business development and sales for one of Athena‘s competitors. Relators Lovell and McKusick operate a home-healthcare service that was one of Athena‘s clients.
On October 30, 2017, Sanborn filed a sealed qui tam complaint against Athena. The complaint alleged that Athena had operated incentive programs to induce purchases of Athena‘s services in violation of the Anti-Kickback Statute,
Roughly two months later, on December 21, 2017, Lovell and McKusick filed a separate qui tam complaint against Athena. They amended that complaint on April 18, 2018. Like Sanborn, Lovell and McKusick alleged that Athena‘s incentive programs violated the Anti-Kickback Statute (again, the “Kickback Claim“). They also alleged that Athena‘s billing software submitted false claims for services (the “Billing Claim“).
On January 27, 2021, the government, the relators, and Athena entered into a settlement agreement, which settled both the Kickback Claims in which the government had intervened and the relators’ remaining claims.1 Athena agreed to pay the government (not the relators) over $18,250,000. The settlement agreement stated that “[i]t is understood by all the Parties that Relator Sanborn and Relators Lovell and McKusick have reached their own agreement regarding their respective shares of any funds paid by the United States to Relator Sanborn.” The settlement agreement
also reserved the relators’ ability to seek, and Athena‘s ability to contest, payment of attorneys’ fees pursuant to
In February 2021, the government and the relators executed a separate agreement. The parties agree that, pursuant to this agreement, the government paid an agreed amount to Sanborn on March 15, 2021. Under the terms of the private agreement among the relators, not involving the government or Athena, Sanborn paid to Lovell and McKusick a sum purporting to be part of the payment he received from the government. The sum paid is not in evidence.
C.
Both sets of relators sought an award of attorneys’ fees from the district court under
The district court denied Lovell and McKusick‘s motion for attorneys’ fees and denied Sanborn‘s motion in part. Athenahealth, 2022 WL 658654, at *8. As to Lovell and McKusick, the court held that they were barred from recovering fees for their Kickback Claim under
to Sanborn, the court held that he was entitled to fees under
These timely appeals followed. The government has not taken a position in either appeal.
II.
We review questions of statutory interpretation de novo. See Baker v. Smith & Wesson, Inc., 40 F.4th 43, 47 (1st Cir. 2022). These consolidated appeals turn on relators’ entitlement to attorneys’ fees under the text of
A.
We begin with Lovell and McKusick‘s claim to attorneys’ fees for their Kickback Claim under
“As always in matters of statutory interpretation, we start with the text.” United States v. Millennium Lab‘ys, Inc., 923 F.3d 240, 250 (1st Cir. 2019). Reasonable attorneys’ fees may be awarded pursuant to
If the Government proceeds with an action brought by a person under subsection (b), such person shall, subject to the second sentence of this paragraph, receive at least 15 percent but not more than 25 percent of the proceeds of the action or settlement of the claim, depending upon the extent to which the person substantially contributed to the prosecution of the action. Where the action is one which the court finds to be based primarily on disclosures of specific information (other than information provided by the person bringing the action) relating to allegations
or transactions in a criminal, civil, or administrative hearing, in a congressional, administrative, or Government Accounting Office report, hearing, audit, or investigation, or from the news media, the court may award such sums as it considers appropriate, but in no case more than 10 percent of the proceeds, taking into account the significance of the information and the role of the person bringing the action in advancing the case to litigation. Any payment to a person under the first or second sentence of this paragraph shall be made from the proceeds. Any such person shall also receive an amount for reasonable expenses which the court finds to have been necessarily incurred, plus reasonable attorneys’ fees and
costs. All such expenses, fees, and costs shall be awarded against the defendant.
The next-to-last sentence provides that “[a]ny such person shall also receive . . . reasonable attorneys’ fees.”
a payment “under the first or second sentence” of
There are two conditions for receipt of a relator‘s share within the meaning of the statute that are stated in the first sentence of
By its terms,
percent but not more than 25 percent of the proceeds.”
Other courts have agreed that relators do not receive a statutory relator‘s share when they receive funds via a private sharing agreement. See, e.g., United States ex rel. McNeil v. Jolly, 451 F. Supp. 3d 657, 668-69 (E.D. La. 2020); United States v. NextCare, Inc., No. 11-cv-141, 2013 WL 431828, at *2-3 (W.D.N.C. Feb. 4, 2013).
This conclusion is supported by the FCA‘s overall statutory scheme. The FCA affords the government broad authority and contemplates that the government will serve a gatekeeping function. See, e.g.,
Relators do not receive a relator‘s share within the meaning of the statute, see
B.
We next consider Sanborn‘s claim to attorneys’ fees for work on his EHR Compliance Claim, in which the government did not
Notes
intervene.8 In the district court, Sanborn moved for fees solely pursuant to
The relevant language in
As then-Judge Alito recognized in United States ex rel. Merena v. SmithKline Beecham Corp., 205 F.3d 97 (3d Cir. 2000), one “quirk[]” of the FCA is that “the statute is based on the model of a single-claim complaint” even though many qui tam actions involve multiple claims. Id. at 101. For example, a qui tam plaintiff is authorized to “bring a civil action for a violation of section 3729.”
government may then either “proceed with the action” or “decline[] to take over the action.”
In the years since Rockwell, the weight of authority, including in our circuit, has continued to utilize a claim-by-claim analysis in applying the FCA‘s qui tam provisions. See, e.g., Millennium, 923 F.3d at 253 (proceeding claim-by-claim in conducting a first-to-file analysis); United States ex rel. Schumann v. Astrazeneca Pharms. L.P., 769 F.3d 837, 846 (3d Cir. 2014) (“[The] FCA‘s reference to ‘action’ may reasonably be read to mean ‘claim’ because the statute envisions a single-claim complaint.” (citing Merena, 205 F.3d at 101-02)); United States ex rel. Rauch v. Oaktree Med. Ctr., P.C., No. 15-cv-01589, 2020 WL 1065955, at *9 (D.S.C. Mar. 5, 2020) (noting this “well-established interpretation of the FCA“).
We apply this construction here and hold that government intervention in an “action” under the first sentence of
We are not swayed by Sanborn‘s arguments to the contrary. Sanborn points out that
But the canon against surplusage is not an absolute rule, and may not be “a particularly useful guide to a fair construction of [a] statute” where the statute at issue reflects “inartful drafting.” King v. Burwell, 576 U.S. 473, 491 (2015). Such is the case here. One of the FCA‘s unusual features is its use of “claim” and “action” interchangeably to refer to a case. See, e.g., United States ex rel. Garbe v. Kmart Corp., 824 F.3d 632, 641 (7th Cir. 2016) (recognizing “Congress‘s free use of ‘claim’ (along with ‘action‘) to mean ‘civil action’ throughout the FCA“); United States ex rel. Int‘l Bhd. of Elec. Workers Loc. Union No. 98 v. Farfield Co., 5 F.4th 315, 331 (3d Cir. 2021) (similar); Sanders v. Allison Engine Co., 703 F.3d 930, 939 (6th Cir. 2012) (similar); cf. Kellogg Brown & Root Servs., Inc. v. United States ex rel. Carter, 575 U.S. 650, 664 (2015)
(noting the “many interpretive challenges” presented by the FCA‘S qui tam provisions). In context,
Sanborn also argues that Merena and Rockwell are distinguishable because they interpreted
inaction lacks persuasive significance’ in most circumstances.” Star Athletica, L.L.C. v. Varsity Brands, Inc., 137 S. Ct. 1002, 1015 (2017) (alteration in original) (quoting Pension Benefit Guar. Corp. v. LTV Corp., 496 U.S. 633, 650 (1990)). Because the government did not intervene in Sanborn‘s EHR Compliance Claim, he is not entitled under
We reject Sanborn‘s argument that he is entitled to recover all fees associated with his EHR Compliance Claim for the independent reason that work on that claim was useful and necessary to the settlement of the Kickback Claim. The district court considered both claims and concluded that the EHR Compliance Claim was “substantially more complex than the [Kickback Claim] and comprised the majority of [Sanborn‘s] complaint,” that the claims were “not substantially interconnected,” and that the claims’ “operative legal theories were distinct.” Athenahealth, 2022 WL 658654, at *7. Even so, the district court recognized some potential synergies between the claims and thus reduced Sanborn‘s
lodestar by 50 percent rather than the 70 percent proposed by Athena. See id. This was not an abuse of discretion. See Perez-Sosa v. Garland, 22 F.4th 312, 320 (1st Cir. 2022).
Sanborn argues in the alternative that he is entitled to fees under
III.
For the foregoing reasons, we affirm the district court.